Approval for Genentech's vismodegib marked the first approval for a Hedgehog inhibitor, but questions remain for the class's broader role in other cancers.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Guha, M. Hedgehog inhibitor gets landmark skin cancer approval, but questions remain for wider potential. Nat Rev Drug Discov 11, 257–258 (2012). https://doi.org/10.1038/nrd3714
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd3714
This article is cited by
-
Protein arginine methyltransferase 1 interacts with Gli1 and regulates its transcriptional activity
Tumor Biology (2016)
-
Berberine, a natural compound, suppresses Hedgehog signaling pathway activity and cancer growth
BMC Cancer (2015)
-
AT-101 inhibits hedgehog pathway activity and cancer growth
Cancer Chemotherapy and Pharmacology (2015)
-
GPCR-like signaling mediated by smoothened contributes to acquired chemoresistance through activating Gli
Molecular Cancer (2014)
-
Expression of Hedgehog ligand and signal transduction components in mutually distinct isocitrate dehydrogenase mutant glioma cells supports a role for paracrine signaling
Journal of Neuro-Oncology (2014)
